ubmslateRN-logo-ubm

RN Mobile Menu

Search form

Topics:

Adalimumab-atto: It’s Indications and Key Takeaways

Adalimumab-atto: It’s Indications and Key Takeaways

  • (©Zonda/Shutterstock.com)
  • (1) U.S. FDA news release issued on Sept. 23, 2016: “FDA approves Amjevita, a biosimilar to Humira.”
  • (2) Jyoti Velayudhan, Yuh-feng Chen, et. al. "Demonstration of Functional Similarity of Proposed Biosimilar ABP 501 to Adalimumab," August 2016. BioDrugs. DOI: 10.1007/s40259-016-0185-2
  • (2) Jyoti Velayudhan, Yuh-feng Chen, et. al. "Demonstration of Functional Similarity of Proposed Biosimilar ABP 501 to Adalimumab," August 2016. BioDrugs. DOI: 10.1007/s40259-016-0185-2
  • (2) Jyoti Velayudhan, Yuh-feng Chen, et. al. "Demonstration of Functional Similarity of Proposed Biosimilar ABP 501 to Adalimumab," August 2016. BioDrugs. DOI: 10.1007/s40259-016-0185-2
  • (3) Liu J, Eris T, et. al. "Assessing Analytical Similarity of Proposed Amgen Biosimilar ABP 501 to Adalimumab," July 26 2016. BioDrugs. DOI: 10.1007/s40259-016-0184-3\
  • (3) Liu J, Eris T, et. al. "Assessing Analytical Similarity of Proposed Amgen Biosimilar ABP 501 to Adalimumab," July 26 2016. BioDrugs. DOI: 10.1007/s40259-016-0184-3\
On Sept, 23, the U.S. Food and Drug Administration approved adalimumab-atto (Amjevita, Amgen, Inc.) as a biosimilar to adalimumab (Humira, AbbVie, Inc.) for multiple inflammatory diseases. (1) In this slideshow, we summarize it's approved indications and key takeaways as stated by Amgen researchers who published new trial results this summer.
References: 

(1)    U.S. FDA news release issued on Sept. 23, 2016:  “FDA approves Amjevita, a biosimilar to Humira.”

(2)    Jyoti Velayudhan, Yuh-feng Chen, et. al. "Demonstration of Functional Similarity of Proposed Biosimilar ABP 501 to Adalimumab," August 2016. BioDrugs. DOI: 10.1007/s40259-016-0185-2

(3)    Liu J, Eris T, et. al. "Assessing Analytical Similarity of Proposed Amgen Biosimilar ABP 501 to Adalimumab," July 26 2016. BioDrugs. DOI:  10.1007/s40259-016-0184-3\

 

Add new comment

 
Loading comments...

By clicking Accept, you agree to become a member of the UBM Medica Community.